Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine presented two-year data from the Phase 3 CAHtalyst Pediatric study showing that CRENESSITY slows bone age progression and improves predicted adult height in children with classic congenital adrenal hyperplasia. Among 24 patients with advanced bone age at baseline, mean bone age SDS decreased by 1.12, and a subset of 9 patients saw reductions greater than two standard deviations, correlating with a 4.7 cm increase in predicted adult height.
Key figures
- Drug Name
- CRENESSITY (crinecerfont)
- Phase Of Trial
- Phase 3
- Caregiver survey n
- 29
- Caregiver satisfaction rate
- 100%
- Pediatric patients evaluated
- 41
- Patients with advanced bone age
- 24
- Patients with sds reduction gt 2
- 9
- Mean predicted adult height increase cm
- 4.7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.